Clinical Trials Browser

Phase 1/2 × Disorders of Sex Development × Clear all

NCT06239272 2026-01-26

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Phase 1/2 Terminated

133 enrolled 10 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development